Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 6/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20722632 | 0.91 | MAP4K4 (0.37) | JAK3BTKMAP4K4PDE10ACKS1B | |
| SCHEMBL20722776 | 0.89 | CA1 (0.45) | PDE10ACKS1BSKP1SKP2KMT2A | |
| SCHEMBL28567919 | 0.89 | CA1 (0.45) | PDE10ACKS1BSKP1SKP2KMT2A | |
| SCHEMBL28567921 | 0.89 | CA1 (0.45) | PDE10ACKS1BSKP1SKP2KMT2A | |
| SCHEMBL30968500 | 0.89 | CA1 (0.45) | PDE10ACKS1BSKP1SKP2KMT2A | |
| SCHEMBL21684799 | 0.88 | MAP4K4 (0.37) | JAK3BTKMAP4K4PDE10ACKS1B | |
| SCHEMBL31204568 | 0.88 | MAP4K4 (0.37) | JAK3BTKMAP4K4PDE10ACKS1B | |
| SCHEMBL20722733 | 0.88 | MAP4K4 (0.37) | JAK3BTKMAP4K4PDE10ACKS1B | |
| SCHEMBL20722735 | 0.88 | MAP4K4 (0.37) | JAK3BTKMAP4K4PDE10ACKS1B | |
| SCHEMBL30062024 | 0.88 | MAP4K4 (0.37) | JAK3BTKMAP4K4PDE10ACKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | JAK3 1862/4885BTK 3255/4885MAP4K4 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.